Clinical trials: Gout Flare
Infection, Heart Failure
Prediction of Expected Length of Hospital Stay Using Machine Learning
This is a retrospective observational study drawing on data from the Brigham and Women's Home Hospital database. Sociodemographic and clinic data from a training cohort were used to train a machine learning algorithm to predict…
- Conditions
- Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma
- Trial name
- NCT04784351
- Where
- 2 sites in United States
- Sponsor
- Brigham and Women's Hospital
Acute Kidney Injury, Sepsis
Novel Biomarkers for Early Renal Injury in Children With Sepsis
Toxicosis often leads to multiple organ failure (MODS), with the kidney being the primary target organ due to its sensitivity to infection and ischemia.
- Conditions
- Acute Kidney Injury, Sepsis, Gout Flare
- Trial name
- NCT06197828
- Testing
- This study is an observational studie which have no intervention
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Acute Gouty Arthritis
Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
This study assessed the safety and efficacy of canakinumab pre-filled syringes in comparison to triamcinolone acetonide 40 mg and canakinumab lyophilizate in patients that have frequent flares of acute gouty arthritis.
- Trial name
- NCT01356602
- Testing
- Canakinumab pre-filled syringe, Canakinumab lyophilized powder, Triamcinolone Acetonide
- Where
- 99 sites in United States, Canada and 3 more
- Volunteers
- 397 people
- Sponsor
- Novartis Pharmaceuticals
Gout
The Impact of Initiating Dotinurad Urate-Lowering Therapy at Different Time Windows on Gout Flare Resolution Time
To confirm that initiating Dotinurad for uric acid uric acid lowering during the acute phase of gout is non-inferior to initiating it after the acute phase of gout has subsided, and to analyze whether initiating Dotinurad…
- Trial name
- NCT07661030
- Testing
- Dotinurad, colchicine, etoricoxib
- Volunteers
- 142 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Acute Gouty Arthritis, Gout Flare
Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare
A randomized, double-blind, international multicenter, colchicine and placebo-controlled study to evaluate the efficacy and safety of ABP-745 in subjects with acute gout.
- Conditions
- Acute Gouty Arthritis, Gout Flare, Gout Flares, Acute Gout Flare
- Trial name
- NCT07145229
- Testing
- ABP-745 Dose A, ABP-745 Dose B, Colchicine
- Where
- 38 sites in United States, Australia and 1 more
- Volunteers
- 380 people
- Sponsor
- Atom Therapeutics Co., Ltd
Gout
Colchicine Or Naproxen Treatment for ACute gouT
Gout is the most common cause of inflamed joints affecting 1.4% of adults in the UK. Most patients are treated entirely in general practice yet primary care management is frequently suboptimal.
- Trial name
- CONTACT (NCT01994226)
- Testing
- Low-dose colchicine, Naproxen 750 mg/250 mg
- Where
- United Kingdom
- Volunteers
- 399 people
- Sponsor
- Keele University
Acute Gout
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.
The purpose of this study was to demonstrate that canakinumab given upon acute gout flares relieves the signs and symptoms and prevents recurrence of gout flares in patients with frequent flares of gout for whom non-steroidal…
- Trial name
- β-RELIEVED-II (NCT01080131)
- Testing
- Canakinumab 150 mg, Triamcinolone acetonide 40 mg
- Where
- 108 sites in United States, Canada and 3 more
- Volunteers
- 226 people
- Sponsor
- Novartis Pharmaceuticals
Primary Gout and Hyperuricemia
The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia
SHR4640 tablets is a highly selective and potent URAT1 inhibitors. The study is being conducted to evaluate the efficacy, and safety of SHR4640 tablet combined with 40 mg/d febuxostat tablet in reducing uric acid in subjects with…
- Trial name
- NCT07362355
- Testing
- SHR4640 ；Febuxostat, SHR4640 ; Febuxostat, SHR4640
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Acute Gouty Arthritis
Efficacy and Safety of Lumiracoxib 400 mg Once Daily in Acute Flares of Gout
This study is designed to develop our understanding of the efficacy and safety of using lumiracoxib in the treatment of patients with acute gout.
- Trial name
- NCT00170781
- Testing
- Lumiracoxib
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 234 people
- Sponsor
- Novartis
Infection, Heart Failure
Prediction of 30-Day Readmission Using Machine Learning
This is a retrospective observational study drawing on data from the Brigham and Women's Home Hospital database. Sociodemographic and clinic data from a training cohort were used to train a machine learning algorithm to predict…
- Conditions
- Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma
- Trial name
- NCT04849312
- Where
- 2 sites in United States
- Volunteers
- 372 people
- Sponsor
- Brigham and Women's Hospital
Gout
Does Allopurinol Prolong a Treated, Acute Gout Flare?
This is a double blind placebo controlled study to determine whether starting allopurinol during a treated acute gout attack will have any effect on the duration of the attack.
- Trial name
- NCT01988402
- Testing
- allopurinol
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- 59th Medical Wing
Acute Gout Arthritis, Acupuncture
Immediate Analgesic Effects of Cheek Acupuncture for Acute Gouty Arthritis
The goal of this clinical trial is to evaluate the immediate analgesic effect and patients' evaluation of the treatment of cheek acupuncture in patients with acute gouty arthritis.
- Conditions
- Acute Gout Arthritis, Acupuncture, Acute Pain
- Trial name
- CAAGA (NCT06001112)
- Testing
- cheek acupuncture, Etoricoxib
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
Gout Flare
24-Week Recurrence Rate of Gout Following Firsekibart Treatment
Study Objective: To evaluate the 24-week recurrence rate and safety of Firsekibart in patients with acute gouty arthritis in a real-world clinical setting.
- Trial name
- NCT07625514
- Testing
- Firsekibart
- Where
- 11 sites in China
- Volunteers
- 264 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Gout
MPC-004 for the Treatment of an Acute Gout Flare
This study is a multicenter, randomized, double-blind, placebo-controlled, parallel group, dose-comparison to determine the efficacy and safety of a standard-dose of colchicine (4.8 mg) versus low-dose colchicine (1.8 mg) or…
- Trial name
- AGREE (NCT00506883)
- Testing
- High Dose Colchicine (4.8 mg total dose), Low Dose Colchicine (1.8mg total dose)
- Where
- 83 sites in United States
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- Takeda
Acute Gout
A Study Evaluating the Effect of Etoricoxib and Indomethacin in the Treatment of Acute Gout (0663-081)(COMPLETED)
A study to evaluate the effects of etoricoxib and indomethacin in the treatment of acute gout.
- Trial name
- NCT00142558
- Testing
- MK0663; etoricoxib / Duration of Treatment: 5 Days, Comparator: indomethacin 75 mg sustained release capsule / Duration of Treatment: 5 Days
- Volunteers
- 180 people
- Sponsor
- Organon and Co
Gout Flare
Efficacy and Safety of Simiaowan in Prevention of Acute Flares in Chronic Gout Patients Initiating Febuxostat Therapy
The aim of this study is to evaluate the efficacy and safety of simiaowan in prevention of acute flares in chronic gout patients initiating febuxostat therapy.
- Trial name
- NCT04069325
- Testing
- simiaowan, febuxostat
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Gouty Arthritis
Long Term Study of Canakinumab (ACZ885) in Patients With Gout
This 24-week open-label extension study is designed to provide additional long-term safety data up to a total of 1-year for patients rolling over from the core study, and to collect further efficacy and tolerability data for all…
- Trial name
- NCT00927810
- Testing
- Canakinumab
- Where
- 45 sites in United States, Argentina and 16 more
- Volunteers
- 341 people
- Sponsor
- Novartis Pharmaceuticals
Arthritis, Gouty
Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout
This is an exploratory proof-of-concept study to evaluate the safety and efficacy of canakinumab (ACZ885) for inflammation and pain associated with acute gouty arthritis.
- Trial name
- NCT00663169
- Testing
- canakinumab, dexamethasone
- Where
- 4 sites in United States, Switzerland and 1 more
- Volunteers
- 6 people
- Sponsor
- Novartis
Gout, Acute Gout Flare
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers
A randomized, double-blind, placebo-controlled, dose-escalation study will be conducted in healthy volunteers. This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ABP-745 following single (Part 1) and…
- Conditions
- Gout, Acute Gout Flare, Gout Flares
- Trial name
- ABP-745 (NCT06258213)
- Testing
- ABP-745
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Atom Therapeutics Co., Ltd
Gout Flares
A Proof-of-Concept Study of AC-201 to Prevent Gout Flares
Initiation of ULT for gout increases the occurrence of acute gouty arthritis flares due to mobilization of urate from tissue deposits. IL-1β plays a key role in mediating the inflammatory response in gouty arthritis.
- Trial name
- NCT01712204
- Testing
- AC-201, Febuxostat
- Where
- Taiwan
- Volunteers
- 82 people
- Sponsor
- TWi Biotechnology, Inc.